Welcome to our dedicated page for Rapport Therapeutics SEC filings (Ticker: RAPP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Rapport Therapeutics鈥� SEC disclosures can feel like reading a Ph.D. thesis鈥攖rial protocols, receptor binding data, and pages of R&D spend hide the nuggets investors need. Whether you are searching for the next 8-K on interim RAP-219 results or trying to decode executive options grants, the complexity is real.
Stock Titan solves that problem. Our AI engine skims every newly posted document on EDGAR, extracts what matters, then delivers plain-English takeaways in seconds. From the Rapport Therapeutics quarterly earnings report 10-Q filing to an unexpected 8-K clinical update, you鈥檒l see cost run-rates, milestone guidance, and cash runway highlighted automatically. Need ownership intel? Receive alerts for Rapport Therapeutics insider trading Form 4 transactions and view Rapport Therapeutics Form 4 insider transactions real-time, complete with context鈥攚as the purchase timed around trial data?
Here鈥檚 what you can uncover on this page:
- 10-K & 10-Q: R&D expense trends, pipeline status, and our Rapport Therapeutics annual report 10-K simplified summary.
- 8-K: Key study readouts and financings with Rapport Therapeutics 8-K material events explained.
- Form 4: Track Rapport Therapeutics executive stock transactions Form 4 and spot buying or selling pressure.
- DEF 14A proxy: Review Rapport Therapeutics proxy statement executive compensation without combing through tables.
Still wondering how to make sense of biotech jargon? Try understanding Rapport Therapeutics SEC documents with AI. Our platform pairs every filing with concise commentary, ratios, and red-flag alerts so you can finish your Rapport Therapeutics earnings report filing analysis before the market opens.
Rapport Therapeutics describes RAP-219, an AMPAR negative allosteric modulator designed to target TARP纬8 to achieve neuroanatomical specificity for focal epilepsy and other CNS indications. In a Phase 2a safety population of 30 patients, the company reports topline efficacy in refractory focal-onset seizures: 85.2% of patients achieved 鈮�30% reduction in LEs and 72.0% achieved 鈮�50% reduction (both p<0.0001); median and higher-responder results were reported and detailed follow-up analyses are ongoing. The company states RAP-219 was generally well tolerated with four discontinuations during treatment, three attributed to TEAEs.
The filing also discloses an FDA clinical hold specific to the IND for diabetic peripheral neuropathic pain that requested protocol amendments; this hold has not affected the ongoing focal epilepsy trial. The company outlines development plans including additional follow-up results, a long-term safety trial, planned Phase 3 initiation, and further PK and PET data releases as part of its clinical pathway. The prospectus supplement stresses risks, forward-looking uncertainties, and references incorporated SEC filings for more detail.
Rapport Therapeutics (RAPP) Form 144 notice reports a proposed sale of common stock. The filer intends to sell 10,000 shares through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $143,600. The shares represent a portion of 36,497,920 shares outstanding. The securities were acquired and are to be sold on 09/08/2025 following an exercise of stock options, with cash payment recorded. The filer certifies no undisclosed material adverse information and provides the required Rule 144 representations.
Rapport Therapeutics reported topline Phase 2a efficacy for RAP-219 in drug-resistant focal onset seizures showing strong short-term clinical responses. In the 8-week treatment period, 85.2% of patients achieved a 鈮�30% reduction in lifetime events (LEs) from baseline, 72.0% achieved a 鈮�50% reduction in clinical seizures, and 24% achieved seizure freedom; all responder endpoints reported p<0.0001. Median reductions were assessed versus appropriate null hypotheses using Wilcoxon signed rank tests and exact binomial tests for responder rates.
The company said RAP-219 was generally well-tolerated with mostly mild treatment-emergent adverse events and a low discontinuation rate. Rapport noted ongoing 8-week follow-up, plans for Phase 3 trials in focal onset seizures, a Phase 2 bipolar mania study, exploration of a long-acting injectable formulation, and expects initial pharmacokinetic results in 2027. A press release and corporate presentation were furnished and a webcast presentation will be posted on the company website.
Rapport Therapeutics Chief Scientific Officer David Bredt reported sales of common stock under a Rule 10b5-1 plan adopted December 12, 2024. On 08/15/2025 he sold 8,300 shares at a weighted-average price of $14.9769 (trade prices ranged $14.65鈥�$15.50) and sold 200 shares at a weighted-average price of $15.79 (trade prices ranged $15.74鈥�$15.84). The filings show beneficial ownership following those transactions of 426,842 and 426,642 shares, respectively. The Form 4 was signed by attorney-in-fact Troy Ignelzi on 08/18/2025.
FAQ
What is the current stock price of Rapport Therapeutics (RAPP)?
What is the market cap of Rapport Therapeutics (RAPP)?
